PALO
ALTO, Calif., Sept. 10,
2024 /PRNewswire/ -- HepaTx, a biotechnology company
specializing in regenerative medicine, has entered into a license
agreement with Mayo Clinic to advance HepaTx's innovative stem cell
technology into clinical trials. This collaboration aims to develop
and evaluate new therapeutic approaches for liver diseases, with an
initial focus on alcohol-related hepatitis, offering hope to
millions of patients worldwide.
Under the agreement, HepaTx will leverage Mayo Clinic's clinical
research expertise and infrastructure to facilitate the transition
of its proprietary technology, which uses adipose-derived stem
cells for the potential treatment of acute and chronic liver
conditions, from preclinical development to human trials.
"We are very pleased to have the opportunity to work with the
outstanding researchers at Mayo Clinic to advance these potentially
transformative therapies to the clinic. I can think of no better
organization to work with given their outstanding liver disease and
regenerative medicine expertise," commented Eric Schuur, the CEO of HepaTx.
The collaboration is expected to accelerate the development of
HepaTx's cell therapy technology, enabling it to reach the clinical
stage more quickly and efficiently. The overall aim of the effort
is to advance the pipeline of innovative cell therapies that can
potentially transform the treatment landscape for liver disease
patients, improving outcomes and quality of life.
About HepaTx
HepaTx is a cell therapy and regenerative medicine company
developing cell-based treatments for late-stage liver disease, a
highly underserved and cost-intensive market. To learn more, visit
our website, Hepatx.com, and follow us on Twitter, @hepatx, and
LinkedIn.
Mayo Clinic has a financial interest in the technology
referenced in this press release. Mayo will use any revenue it
receives to support its not-for-profit mission in patient care,
education, and research.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hepatx-enters-collaboration-with-mayo-clinic-to-advance-cell-therapy-technology-for-liver-disease-to-clinical-trials-302243375.html
SOURCE HepaTx